Clinical Trials تتوفر أدناه التجارب السريرية الحالية.96 الدراسات في Cardiovascular Diseases and Cardiac Surgery (الدراسات المفتوحة فقط). تصفية قائمة الدراسات هذه حسب الموقع، والحالة والمزيد. Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR) Rochester, Minn. The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR). Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial Rochester, Minn. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke. Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms Rochester, Minn. The purpose of this study is assess the safety and effectiveness of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprost (TAMBE) Device in the treatment of thoracoabdominal and pararenal aortic aneurysms. A Study to Evaluate Aortic Dilatation in Patients with Conotruncal Abnormalities Rochester, Minn. The purpose of this study is to assess operative and postoperative outcomes after aortic valve surgery, evaluate for changes in ascending aorta diameter by comparing pre-operative CT imaging to measurements on follow-up imaging, and examine late outcomes and functional status during the follow-up period with specific focus on mortality, need for re-operation and incidence of aortic dissection. Study to Determine the Accuracy of a New Venous Air Plethysmograph in People with Normal, Incompetent, and Obstructed Venous Hemodynamics. Rochester, Minn. The purpose of this study is to determine the accuracy (sensitivity, specificity, negative predictive value, positive predictive value) of a new venous air plethysmograph in people with normal, incompetent, and obstructed venous hemodynamics. A Repository of Atria Tissue for the Investigation of Atrial Pathophysiology in Patients with Atrial Fibrillation Rochester, Minn. The purpose of this study is to collect surgically removed atrial tissue for genetic, pathologic, metabolic, and molecular studies in patients with or without a history of atrial fibrillation. A Study to Evaluate DDP3 as a Predictor of Cardiogenic Shock in Patients Presenting with Cardiac Symptoms Rochester, Minn. The purpose of this study is to evaluate whether DDP3 identifies patients at early risk of cardiogenic shock presenting with STEMI in order to benefit from more aggressive cardiology scrutiny. A Study to Establish a Registry for the Pulmonary Hypertension Association Jacksonville, Fla. The objectives of this study are to measure and improve quality of care (including assessing differences in adherence to evidence-based guidelines and establishing benchmarks for health outcomes); determine the clinical effectiveness, comparative effectiveness, and cost effectiveness of treatment approaches; understand risk factors for outcomes and regional/center differences; and facilitate funded clinical trials of new therapies and collaboration with the PAH community at large, including providers, patients, and their caregivers. A Study to Assess the Current FDA-approved AliveCor Kardia Device to Measure the QT/QTc in Patients Presenting to the Genetic Heart Rhythm Clinic Rochester, Minn. The purpose of this study is to assess the feasibility of using the current FDA-approved AliveCor Kardia device and their AliveCor Tripod device (FDA Approval pending) to measure the QT/QTc in patients presenting to the Genetic Heart Rhythm Clinic. Post Approval Study for Treatment of Drug-resistant Adult Primary FSGS Using the LIPOSORBER® LA-15 System Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit. التصفّح دراسات سريرية السابقالصفحة السابقة توجّه للصفحة 44 توجّه للصفحة 55 توجّه للصفحة 66 توجّه للصفحة 77 توجّه للصفحة 88 التاليالصفحة التالية المتخصصون في المجالات الطبية Cardiovascular Diseases & Cardiac Surgery clinical-trials